This study evaluates the effect of the therapy combining GA and NAC on disease activity as reflected by MRI parameters while assessing tolerability and safety.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
18
Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
Change in the sum of T1 Gd-enhancing lesions as reflected by MRI
Change in the sum of T1 Gd-enhancing lesions measured at pre-treatment (weeks -10 \[screening\], -6 and 0 \[baseline\]) to the sum of T1 Gd-enhancing lesions measured in the last study trimester (weeks 28, 32 and 36 \[termination\]).
Time frame: 46 weeks
MRI parameters
Evaluation of secondary efficacy MRI parameters and assessments of tolerability and safety.
Time frame: 46 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.